United States · 
What does Longview Ventures invest in?
Longview Ventures invests most often at Series B and Seed (56% of the rounds on record), in sectors such as Healthcare, Medtech and Biotech.
Longview Ventures highlights
- 01
9 rounds on record
- 02
Mostly Series B and Seed: 56% of its rounds
- 03
Sole investor in 2 rounds, median $1.4M
- 04
1 exits from the portfolio
What they do
Broadview’s mission is to accelerate the development of promising technology for the diagnosis and treatment of cardiovascular disease and stroke through targeted investments.From their own website
- Type
- VC firm (from a list, unverified)
- Cheque size
- Not stated
- Stages
- SeedSeries ASeries B
- Sectors
- HealthcareMedtechBiotech
- Based in
- Boston, United States
- Cold pitches
- Accepted
The record
Every round we can evidence, newest first9 appearances
- 2025
1 round
- May
- 2024
1 round
- Dec
- 2020
1 round
- Apr
- 2013
1 round
- Feb
- 2012
2 rounds
- Sept
- Apr
- 2010
1 round
- Dec
- 2009
2 rounds
- Jun
- May
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
We hold 9 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What they claim to have backed
From their own portfolio page (on their website)
27 of 46 we have independently watched raise
AcesionpharmaAdientmedicalAeromicsAlleviantmedicalAlveronAntagtherapeuticsAriacvAtacorBaskingbiosciencesBiokierCapricorCardiosenseComanchebiopharmaCorideaCroivalveEpiriumFineheartGilatherapeuticsGiwindowsInfobionicIschemiacareIsomabLyratherapeuticsNyramedicalPulmokineRemedypharmaceuticalsXiimedicalAggaminAscensionventuresBoston Web DesignCorflowDecimmuneGraftsolutionsHerantisI3-nirfInnovationsincrmMaxwellbiomedicalMellitushealthMosannaNupulsecvPuzzlemedRapidpulsemedReliefcardioVectoriousmedtechViridiantherapeuticsZzbiotech
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
Exits from the portfolio
Companies it backed that were later bought or listed1 in all
CardiAQ Valve TechnologiesBought by Edwards Lifesciences$350MJul 2015
An exit counts when it came after the firm's first round in the company. From historical deal records.